Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Trial Type:  Treatment
Treatment/Intervention:  immunomodulation therapy, immunotherapy
Trial Status:  Active
Results 1-25 of 3374 for your search:
Start Over
Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: POI-02818, NIP-02-005, NCT00131313
German Multicenter Trial for Treatment of Elderly Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 55
Sponsor: Other
Protocol IDs: GMALL02, NCT00198978
German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 65
Sponsor: Other
Protocol IDs: GMALL01, NCT00198991
Efficacy of G-CSF-Priming in Elderly AML Patients
Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 60
Sponsor: Other
Protocol IDs: AML-elderly 01/99 Trial, NCT00199147
An Expanded Access Program For Lenalidomide Plus Dexamethasone In Previously Treated Subjects With Multiple Myeloma
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-MM-016, FHCRC-2068.00, CELGENE-CC-5013-MM-016, NCT00179647
Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.
Phase: Phase IV
Type: Treatment
Status: Active
Age: 15 to 60
Sponsor: Other
Protocol IDs: Hemato INCAN 01/2007, NCT00429065
Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UMCNONCO200801, NCT00777504
Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: HEMOS ALL1105, NCT00797810
Imiquimod 5% Cream for the Treatment of Periocular Basal Cell Carcinoma
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 90
Sponsor: Other
Protocol IDs: 0559/07, NCT00803907
Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC)
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: simcere002, simcere0802, NCT00813332
A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC)
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: SIM090801, NCT01028729
A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001LIC01, NCT01206764
Study of Concurrent Chemo-radiotherapy Combined With Recombinant Human Endostatin for Local Advanced Non-small Cell Lung Cancer (NSCLC)
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 18 to 70
Sponsor: Pharmaceutical / Industry
Protocol IDs: sim201002, NCT01211002
Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SHCZH-2010-CT-001, NCT01249690
An Open Label, Single Arm Trial to Characterize Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CRAD001LDE36T, 2010-021370-11, NCT01266837
Busulfan and Cyclophosphamide Instead of Total Boby Irradiation (TBI) and Cyclophosphamide for Hematological Malignancies Hematocrit (HCT)
Phase: Phase IV
Type: Treatment
Status: Approved-not yet active
Age: 21 and under
Sponsor: Other
Protocol IDs: TASMC-11-MB-442-CTIL, NCT01339988
Imiquimod 3.75% Cream in Combination With Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses
Phase: Phase IV
Type: Prevention, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 10-0933, NCT01229319
Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1)
Phase: Phase IV
Type: Treatment
Status: Active
Age: 6 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001MIL04T, NCT01365468
Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SG 327/10, NCT01402089
Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC)
Phase: Phase IV
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: 2011PTAHCC, NCT01409499
Correlation Between RECIST, Morphologic Response by CT- Histopathologic Response in Hepatic Metastasis Secondary to Colorectal Cancer
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: GEMCAD-1006, NCT01493713
MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I
Phase: Phase IV
Type: Diagnostic, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: P0334, NCT01501487
Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CRAD001LDE43, 2011-003416-23, NCT01514448
First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and ove
Sponsor: Other
Protocol IDs: iOM-605, 2011-001138-40, NCT01521715
Start Over